Tc Bio Pharm (Holdings) PLC TCBP
We take great care to ensure that the data presented and summarized in this overview for TC BioPharm (Holdings) plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TCBP
Top Purchases
Top Sells
About TCBP
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Insider Transactions at TCBP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 30
2022
|
Diana Elizabeth Randall > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
70,000
+50.0%
|
$350,000
$5.0 P/Share
|
|
Nov 30
2022
|
Mark Edward Randall > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
70,000
+15.45%
|
$350,000
$5.0 P/Share
|
|
Nov 30
2022
|
Kenneth Edward Randall > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
70,000
+15.45%
|
$350,000
$5.0 P/Share
|
|
Nov 30
2022
|
Renaissance Capital Partners LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
70,000
+33.84%
|
$350,000
$5.0 P/Share
|
|
May 24
2022
|
Kenneth Edward Randall > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
20,803
+17.16%
|
$20,803
$1.15 P/Share
|